2025 Q4 -tulosraportti
83 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | CAR | NON | ||
| 2 654 | NRD | NON | ||
| 94 | CAR | NON | ||
| 569 | NON | NON | ||
| 154 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuuPAR IS THE FOUNDATION FOR NEXT GENERATION THERANOSTICS PLATFORMS ☢️ uPAR is a protein located on the surface of cells. In many cancers, it is found at high levels on aggressive cancer cells and in the tissue surrounding the tumor. uPAR makes it possible to find and treat the most aggressive cancer cells across different cancer types. uPAR is also closely linked to tumor invasion, growth, and aggressive disease biology. This makes the platform particularly interesting in cancers with high mortality and a large unmet medical need. uPAR is a real platform target in next-generation theranostics. 1. uPAR IS NOT A NICHE TARGET🔥 uPAR is not a narrow theranostics target bound to a single cancer type. uPAR is found across large parts of solid tumors such as glioblastoma, breast cancer, prostate cancer, and pancreatic cancer. This means that the same biological target can potentially be used in several different cancer indications and therapeutic programs. This is precisely the type of biological breadth that can form the basis for a real theranostics platform. 2. ONE TARGET - BOTH IMAGING AND THERAPY Curasight is well underway with building the next-generation theranostics platform. uTRACE uses uPAR to find the aggressive cancer cells. uTREAT uses the same biological target for treatment. uPAR makes it possible to identify, select, and treat patients with the same biological target. One biological target for both imaging and therapy. What is special about uPAR is that the target is both pan-tumor, closely linked to aggressive disease biology, and directly applicable to both patient selection and therapy. This is precisely the type of platform logic Big Pharma demands in theranostics.☢️ 3. IT FITS PERFECTLY INTO BIG PHARMA'S THERANOSTICS STRATEGY. Big Pharma is not just looking for yet another theranostics target, but for platforms that can be used across cancer types, scaled globally, combine imaging and therapy, target aggressive disease biology with a large unmet medical need, and simultaneously be protected by strong and long-lasting IP. Future billion-dollar platforms are not built on narrow niche targets alone, and uPAR already has several of the strategic parameters Big Pharma is looking for. 🔥 As mentioned earlier, SNMMI is the unconditionally most important global conference within theranostics and radiopharma, where all of the above is discussed. Therefore, it will be incredibly exciting to follow uPAR and Andreas Kjær at the conference and any updates regarding uTREAT. 💪
·1 päivä sittenIs there a chance that this will soon change exchange? I mainly use Saxo Bank but one cannot trade with this there, so I have to use Nordnet and therefore not ASK.- ·14.5. · MuokattuSNMMI 2026 IS WHERE THE MARKET CAN NO LONGER IGNORE CURASIGHT ☢️🔥 The target hunt has begun. And Curasight is already at the forefront. The market still prices Curasight as a small Danish biotech. The problem? The theranostics market has already moved on. SNMMI is not just another conference. It is where the cancer target of the future, next-generation theranostics, and new radiopharma platforms are discussed. They are validated and positioned by the global elite. The entire field's center of power gathers there: Big Pharma. capital, the world's leading hospitals, and research. And here, Curasight is already positioned. SNMMI 2026 sends a very clear signal: the uPAR case is no longer niche research. It has moved to the forefront of the discussion about next-generation cancer targets. And no…it's not a poster in the back row!. CURASIGHT IS ALREADY IN THE ROOM WHERE THE TARGETS OF THE FUTURE ARE CHOSEN 🎯 Andreas Kjær is invited to a high-level SNMMI session on: “Identifying and Validating New Molecular Targets and Therapeutic Contexts.” Read that again. It's not about small niche projects! It's about which targets Big Pharma builds next-generation billion-dollar platforms on. That's where the next-generation winners are identified. Curasight is not just participating with a Poster or Oral presentation. Andreas Kjær is not invited to listen. He is invited because uPAR is already part of the discussion about next-generation targets. ☢️ He is an “Invited Faculty Speaker”. He opens the entire CE session with: “Basics of Cancer Biology of Theranostics.” It's about academic authority. And it is extremely prestigious. The prestige scale at top conferences: 1. Poster → “We are participating.” 2. Oral → “The data stands out positively.” 3. Highlighted Oral → “The conference actively highlights the case.” 4. Invited Faculty Speaker → “The field recognizes the platform as important.” 🔥 Andreas is here! 5. Plenary / Keynote → “Top level on the conference's main stage.” It's not retail investor hype. It's the field's highest academic level. https://drive.google.com/file/d/1h1xWz98_W-axjoY57B6fQdoPvIvfRo_o/view?usp=sharing THE THERANOSTICS RACE IS EXPLODING 💥 A global target hunt in radiopharma is currently underway between Novartis, BMS, AstraZeneca, Pfizer, and Eli Lilly. Everyone is chasing the next generation after PSMA, SSTR, and FAP. That is precisely where uPAR is interesting. Big Pharma has already understood something the market still overlooks - future billion-dollar platforms will not be built on a single target. That is precisely why the battle for next-generation targets is exploding right now. And that is precisely why SNMMI matters. IT'S NOT HYPE–IT'S THE THERANOSTICS ELITE 🧠 Andreas Kjær is in the same session as: Mayo Clinic, Mass General, UCLA, and USC. It's not a coincidence. These are the absolute top environments in the theranostics field. When Curasight's founder is in that room, it means one thing: Andreas and uPAR are being taken seriously at the highest academic level in the world. uPAR is no longer niche research. Curasight has already moved into the discussion about next-generation cancer targets.🔥 MARKET VALUE VS POSITIONING The absurd part? Curasight is still priced as a small niche biotech. But the company is already positioned in the middle of the next-generation target discussion in theranostics. That is precisely what the market has not yet understood. The theranostics market, Big Pharma, and capital have moved. The problem? The market still prices Curasight according to old biotech logic. Curasight is already at the forefront of the next-generation theranostics race. 🔥 The abstract will be published shortly. Then we can see the details. Data is King - we need to see it! ⚡
·1 päivä sittenMy reaction is such a classic "oh no, now people are coming in late to a process and are going to unnecessarily hype things up" - I admit that. Have been involved for a long time, am pro cura and believe in both the technology and the future. But really, you're throwing around "analyses" that mostly seem to have been prompted with phrases like, "can you tell me why..:" "isn't it true that ..." "if we now play with the thought that I am right" etc. It's not an analysis, it's online chat 2026 echo chamber logic. A good analysis attributes objectivity and an attempt to illuminate a matter from several different sides (not an attempt to write the story in advance). Good day to you kiddo 
·13.5.Just now at 6.58 AM, I discovered Curasight. Unfortunately, the description of their work here on Nordnet is completely incomprehensible to a layman due to the unusual technical terms used. I therefore asked AI: “Translate the technical terms describing the work of the Danish biotech company Curasight into language a layman can understand”, and received the following answer: “In short, the work of the Danish biotech company Curasight is about finding and irradiating aggressive cancer cells from within, so that healthy tissue is not damaged. Here are the most important technical terms translated into easily understandable language: The biological target uPAR (biomarker / receptor): A type of "antenna" or biological receiver located on the surface of aggressive cancer cells. Healthy cells largely do not have this antenna. Curasight uses this antenna as a homing address. Ligand (Peptide): A small, specially designed molecule (a protein part) that acts like a key. It can precisely lock onto the uPAR antenna on the cancer cell. The technology and methodTheranostics (Theranostics): A word composed of therapy (treatment) and diagnostics (examination). This means that the company uses exactly the same homing molecule to both visualize the cancer on a scanner and then treat it. Radionuclide therapy / Radioligand therapy (RLT): An integrated radiation treatment. A radioactive substance is attached to the homing molecule (the ligand) and injected into the bloodstream. It seeks out the cancer cells itself and destroys them with short-range radiation from within. PET scan (Positron Emission Tomography): An advanced imaging scan that shows the body's biological activity instead of just the physical organs. Curasight's specific productsuTRACE® (Diagnostics): Curasight's scanning method. Here, the homing molecule is coupled with a mild, radioactive tracer. This causes aggressive cancer tumors to "light up" on a PET scanner, so the doctor can see exactly how severe the cancer is. uTREAT® (Treatment): Curasight's treatment method. Here, the same homing molecule is reused, but now it is equipped with a much more powerful, radioactive substance. It functions as a homing missile that delivers radiation directly into the cancer cell without harming the surrounding healthy tissue.”
·12.5.I got a good tip - I thought - and bought, but with a drop of 17 k. it hasn't gone so well so far, and I think it's lying in a straight line and not really moving. Does anyone have an idea where the stock is going, or should I give up and sell?
·14.5.The first ones I bought cost 20,40 DKK, and then I bought more as it fell all the way down to 1,98, which ended up giving me a GAK of 5,39. Now I am happy, but eagerly waiting to see it rise when we get more results
·14.5.I did the same with gak at 7 now in 2 accounts. It was a good offer there at 2 kr😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
83 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuuPAR IS THE FOUNDATION FOR NEXT GENERATION THERANOSTICS PLATFORMS ☢️ uPAR is a protein located on the surface of cells. In many cancers, it is found at high levels on aggressive cancer cells and in the tissue surrounding the tumor. uPAR makes it possible to find and treat the most aggressive cancer cells across different cancer types. uPAR is also closely linked to tumor invasion, growth, and aggressive disease biology. This makes the platform particularly interesting in cancers with high mortality and a large unmet medical need. uPAR is a real platform target in next-generation theranostics. 1. uPAR IS NOT A NICHE TARGET🔥 uPAR is not a narrow theranostics target bound to a single cancer type. uPAR is found across large parts of solid tumors such as glioblastoma, breast cancer, prostate cancer, and pancreatic cancer. This means that the same biological target can potentially be used in several different cancer indications and therapeutic programs. This is precisely the type of biological breadth that can form the basis for a real theranostics platform. 2. ONE TARGET - BOTH IMAGING AND THERAPY Curasight is well underway with building the next-generation theranostics platform. uTRACE uses uPAR to find the aggressive cancer cells. uTREAT uses the same biological target for treatment. uPAR makes it possible to identify, select, and treat patients with the same biological target. One biological target for both imaging and therapy. What is special about uPAR is that the target is both pan-tumor, closely linked to aggressive disease biology, and directly applicable to both patient selection and therapy. This is precisely the type of platform logic Big Pharma demands in theranostics.☢️ 3. IT FITS PERFECTLY INTO BIG PHARMA'S THERANOSTICS STRATEGY. Big Pharma is not just looking for yet another theranostics target, but for platforms that can be used across cancer types, scaled globally, combine imaging and therapy, target aggressive disease biology with a large unmet medical need, and simultaneously be protected by strong and long-lasting IP. Future billion-dollar platforms are not built on narrow niche targets alone, and uPAR already has several of the strategic parameters Big Pharma is looking for. 🔥 As mentioned earlier, SNMMI is the unconditionally most important global conference within theranostics and radiopharma, where all of the above is discussed. Therefore, it will be incredibly exciting to follow uPAR and Andreas Kjær at the conference and any updates regarding uTREAT. 💪
- ·1 päivä sittenIs there a chance that this will soon change exchange? I mainly use Saxo Bank but one cannot trade with this there, so I have to use Nordnet and therefore not ASK.
- ·14.5. · MuokattuSNMMI 2026 IS WHERE THE MARKET CAN NO LONGER IGNORE CURASIGHT ☢️🔥 The target hunt has begun. And Curasight is already at the forefront. The market still prices Curasight as a small Danish biotech. The problem? The theranostics market has already moved on. SNMMI is not just another conference. It is where the cancer target of the future, next-generation theranostics, and new radiopharma platforms are discussed. They are validated and positioned by the global elite. The entire field's center of power gathers there: Big Pharma. capital, the world's leading hospitals, and research. And here, Curasight is already positioned. SNMMI 2026 sends a very clear signal: the uPAR case is no longer niche research. It has moved to the forefront of the discussion about next-generation cancer targets. And no…it's not a poster in the back row!. CURASIGHT IS ALREADY IN THE ROOM WHERE THE TARGETS OF THE FUTURE ARE CHOSEN 🎯 Andreas Kjær is invited to a high-level SNMMI session on: “Identifying and Validating New Molecular Targets and Therapeutic Contexts.” Read that again. It's not about small niche projects! It's about which targets Big Pharma builds next-generation billion-dollar platforms on. That's where the next-generation winners are identified. Curasight is not just participating with a Poster or Oral presentation. Andreas Kjær is not invited to listen. He is invited because uPAR is already part of the discussion about next-generation targets. ☢️ He is an “Invited Faculty Speaker”. He opens the entire CE session with: “Basics of Cancer Biology of Theranostics.” It's about academic authority. And it is extremely prestigious. The prestige scale at top conferences: 1. Poster → “We are participating.” 2. Oral → “The data stands out positively.” 3. Highlighted Oral → “The conference actively highlights the case.” 4. Invited Faculty Speaker → “The field recognizes the platform as important.” 🔥 Andreas is here! 5. Plenary / Keynote → “Top level on the conference's main stage.” It's not retail investor hype. It's the field's highest academic level. https://drive.google.com/file/d/1h1xWz98_W-axjoY57B6fQdoPvIvfRo_o/view?usp=sharing THE THERANOSTICS RACE IS EXPLODING 💥 A global target hunt in radiopharma is currently underway between Novartis, BMS, AstraZeneca, Pfizer, and Eli Lilly. Everyone is chasing the next generation after PSMA, SSTR, and FAP. That is precisely where uPAR is interesting. Big Pharma has already understood something the market still overlooks - future billion-dollar platforms will not be built on a single target. That is precisely why the battle for next-generation targets is exploding right now. And that is precisely why SNMMI matters. IT'S NOT HYPE–IT'S THE THERANOSTICS ELITE 🧠 Andreas Kjær is in the same session as: Mayo Clinic, Mass General, UCLA, and USC. It's not a coincidence. These are the absolute top environments in the theranostics field. When Curasight's founder is in that room, it means one thing: Andreas and uPAR are being taken seriously at the highest academic level in the world. uPAR is no longer niche research. Curasight has already moved into the discussion about next-generation cancer targets.🔥 MARKET VALUE VS POSITIONING The absurd part? Curasight is still priced as a small niche biotech. But the company is already positioned in the middle of the next-generation target discussion in theranostics. That is precisely what the market has not yet understood. The theranostics market, Big Pharma, and capital have moved. The problem? The market still prices Curasight according to old biotech logic. Curasight is already at the forefront of the next-generation theranostics race. 🔥 The abstract will be published shortly. Then we can see the details. Data is King - we need to see it! ⚡·1 päivä sittenMy reaction is such a classic "oh no, now people are coming in late to a process and are going to unnecessarily hype things up" - I admit that. Have been involved for a long time, am pro cura and believe in both the technology and the future. But really, you're throwing around "analyses" that mostly seem to have been prompted with phrases like, "can you tell me why..:" "isn't it true that ..." "if we now play with the thought that I am right" etc. It's not an analysis, it's online chat 2026 echo chamber logic. A good analysis attributes objectivity and an attempt to illuminate a matter from several different sides (not an attempt to write the story in advance). Good day to you kiddo
- ·13.5.Just now at 6.58 AM, I discovered Curasight. Unfortunately, the description of their work here on Nordnet is completely incomprehensible to a layman due to the unusual technical terms used. I therefore asked AI: “Translate the technical terms describing the work of the Danish biotech company Curasight into language a layman can understand”, and received the following answer: “In short, the work of the Danish biotech company Curasight is about finding and irradiating aggressive cancer cells from within, so that healthy tissue is not damaged. Here are the most important technical terms translated into easily understandable language: The biological target uPAR (biomarker / receptor): A type of "antenna" or biological receiver located on the surface of aggressive cancer cells. Healthy cells largely do not have this antenna. Curasight uses this antenna as a homing address. Ligand (Peptide): A small, specially designed molecule (a protein part) that acts like a key. It can precisely lock onto the uPAR antenna on the cancer cell. The technology and methodTheranostics (Theranostics): A word composed of therapy (treatment) and diagnostics (examination). This means that the company uses exactly the same homing molecule to both visualize the cancer on a scanner and then treat it. Radionuclide therapy / Radioligand therapy (RLT): An integrated radiation treatment. A radioactive substance is attached to the homing molecule (the ligand) and injected into the bloodstream. It seeks out the cancer cells itself and destroys them with short-range radiation from within. PET scan (Positron Emission Tomography): An advanced imaging scan that shows the body's biological activity instead of just the physical organs. Curasight's specific productsuTRACE® (Diagnostics): Curasight's scanning method. Here, the homing molecule is coupled with a mild, radioactive tracer. This causes aggressive cancer tumors to "light up" on a PET scanner, so the doctor can see exactly how severe the cancer is. uTREAT® (Treatment): Curasight's treatment method. Here, the same homing molecule is reused, but now it is equipped with a much more powerful, radioactive substance. It functions as a homing missile that delivers radiation directly into the cancer cell without harming the surrounding healthy tissue.”
- ·12.5.I got a good tip - I thought - and bought, but with a drop of 17 k. it hasn't gone so well so far, and I think it's lying in a straight line and not really moving. Does anyone have an idea where the stock is going, or should I give up and sell?·14.5.The first ones I bought cost 20,40 DKK, and then I bought more as it fell all the way down to 1,98, which ended up giving me a GAK of 5,39. Now I am happy, but eagerly waiting to see it rise when we get more results·14.5.I did the same with gak at 7 now in 2 accounts. It was a good offer there at 2 kr😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | CAR | NON | ||
| 2 654 | NRD | NON | ||
| 94 | CAR | NON | ||
| 569 | NON | NON | ||
| 154 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
83 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuuPAR IS THE FOUNDATION FOR NEXT GENERATION THERANOSTICS PLATFORMS ☢️ uPAR is a protein located on the surface of cells. In many cancers, it is found at high levels on aggressive cancer cells and in the tissue surrounding the tumor. uPAR makes it possible to find and treat the most aggressive cancer cells across different cancer types. uPAR is also closely linked to tumor invasion, growth, and aggressive disease biology. This makes the platform particularly interesting in cancers with high mortality and a large unmet medical need. uPAR is a real platform target in next-generation theranostics. 1. uPAR IS NOT A NICHE TARGET🔥 uPAR is not a narrow theranostics target bound to a single cancer type. uPAR is found across large parts of solid tumors such as glioblastoma, breast cancer, prostate cancer, and pancreatic cancer. This means that the same biological target can potentially be used in several different cancer indications and therapeutic programs. This is precisely the type of biological breadth that can form the basis for a real theranostics platform. 2. ONE TARGET - BOTH IMAGING AND THERAPY Curasight is well underway with building the next-generation theranostics platform. uTRACE uses uPAR to find the aggressive cancer cells. uTREAT uses the same biological target for treatment. uPAR makes it possible to identify, select, and treat patients with the same biological target. One biological target for both imaging and therapy. What is special about uPAR is that the target is both pan-tumor, closely linked to aggressive disease biology, and directly applicable to both patient selection and therapy. This is precisely the type of platform logic Big Pharma demands in theranostics.☢️ 3. IT FITS PERFECTLY INTO BIG PHARMA'S THERANOSTICS STRATEGY. Big Pharma is not just looking for yet another theranostics target, but for platforms that can be used across cancer types, scaled globally, combine imaging and therapy, target aggressive disease biology with a large unmet medical need, and simultaneously be protected by strong and long-lasting IP. Future billion-dollar platforms are not built on narrow niche targets alone, and uPAR already has several of the strategic parameters Big Pharma is looking for. 🔥 As mentioned earlier, SNMMI is the unconditionally most important global conference within theranostics and radiopharma, where all of the above is discussed. Therefore, it will be incredibly exciting to follow uPAR and Andreas Kjær at the conference and any updates regarding uTREAT. 💪
- ·1 päivä sittenIs there a chance that this will soon change exchange? I mainly use Saxo Bank but one cannot trade with this there, so I have to use Nordnet and therefore not ASK.
- ·14.5. · MuokattuSNMMI 2026 IS WHERE THE MARKET CAN NO LONGER IGNORE CURASIGHT ☢️🔥 The target hunt has begun. And Curasight is already at the forefront. The market still prices Curasight as a small Danish biotech. The problem? The theranostics market has already moved on. SNMMI is not just another conference. It is where the cancer target of the future, next-generation theranostics, and new radiopharma platforms are discussed. They are validated and positioned by the global elite. The entire field's center of power gathers there: Big Pharma. capital, the world's leading hospitals, and research. And here, Curasight is already positioned. SNMMI 2026 sends a very clear signal: the uPAR case is no longer niche research. It has moved to the forefront of the discussion about next-generation cancer targets. And no…it's not a poster in the back row!. CURASIGHT IS ALREADY IN THE ROOM WHERE THE TARGETS OF THE FUTURE ARE CHOSEN 🎯 Andreas Kjær is invited to a high-level SNMMI session on: “Identifying and Validating New Molecular Targets and Therapeutic Contexts.” Read that again. It's not about small niche projects! It's about which targets Big Pharma builds next-generation billion-dollar platforms on. That's where the next-generation winners are identified. Curasight is not just participating with a Poster or Oral presentation. Andreas Kjær is not invited to listen. He is invited because uPAR is already part of the discussion about next-generation targets. ☢️ He is an “Invited Faculty Speaker”. He opens the entire CE session with: “Basics of Cancer Biology of Theranostics.” It's about academic authority. And it is extremely prestigious. The prestige scale at top conferences: 1. Poster → “We are participating.” 2. Oral → “The data stands out positively.” 3. Highlighted Oral → “The conference actively highlights the case.” 4. Invited Faculty Speaker → “The field recognizes the platform as important.” 🔥 Andreas is here! 5. Plenary / Keynote → “Top level on the conference's main stage.” It's not retail investor hype. It's the field's highest academic level. https://drive.google.com/file/d/1h1xWz98_W-axjoY57B6fQdoPvIvfRo_o/view?usp=sharing THE THERANOSTICS RACE IS EXPLODING 💥 A global target hunt in radiopharma is currently underway between Novartis, BMS, AstraZeneca, Pfizer, and Eli Lilly. Everyone is chasing the next generation after PSMA, SSTR, and FAP. That is precisely where uPAR is interesting. Big Pharma has already understood something the market still overlooks - future billion-dollar platforms will not be built on a single target. That is precisely why the battle for next-generation targets is exploding right now. And that is precisely why SNMMI matters. IT'S NOT HYPE–IT'S THE THERANOSTICS ELITE 🧠 Andreas Kjær is in the same session as: Mayo Clinic, Mass General, UCLA, and USC. It's not a coincidence. These are the absolute top environments in the theranostics field. When Curasight's founder is in that room, it means one thing: Andreas and uPAR are being taken seriously at the highest academic level in the world. uPAR is no longer niche research. Curasight has already moved into the discussion about next-generation cancer targets.🔥 MARKET VALUE VS POSITIONING The absurd part? Curasight is still priced as a small niche biotech. But the company is already positioned in the middle of the next-generation target discussion in theranostics. That is precisely what the market has not yet understood. The theranostics market, Big Pharma, and capital have moved. The problem? The market still prices Curasight according to old biotech logic. Curasight is already at the forefront of the next-generation theranostics race. 🔥 The abstract will be published shortly. Then we can see the details. Data is King - we need to see it! ⚡·1 päivä sittenMy reaction is such a classic "oh no, now people are coming in late to a process and are going to unnecessarily hype things up" - I admit that. Have been involved for a long time, am pro cura and believe in both the technology and the future. But really, you're throwing around "analyses" that mostly seem to have been prompted with phrases like, "can you tell me why..:" "isn't it true that ..." "if we now play with the thought that I am right" etc. It's not an analysis, it's online chat 2026 echo chamber logic. A good analysis attributes objectivity and an attempt to illuminate a matter from several different sides (not an attempt to write the story in advance). Good day to you kiddo
- ·13.5.Just now at 6.58 AM, I discovered Curasight. Unfortunately, the description of their work here on Nordnet is completely incomprehensible to a layman due to the unusual technical terms used. I therefore asked AI: “Translate the technical terms describing the work of the Danish biotech company Curasight into language a layman can understand”, and received the following answer: “In short, the work of the Danish biotech company Curasight is about finding and irradiating aggressive cancer cells from within, so that healthy tissue is not damaged. Here are the most important technical terms translated into easily understandable language: The biological target uPAR (biomarker / receptor): A type of "antenna" or biological receiver located on the surface of aggressive cancer cells. Healthy cells largely do not have this antenna. Curasight uses this antenna as a homing address. Ligand (Peptide): A small, specially designed molecule (a protein part) that acts like a key. It can precisely lock onto the uPAR antenna on the cancer cell. The technology and methodTheranostics (Theranostics): A word composed of therapy (treatment) and diagnostics (examination). This means that the company uses exactly the same homing molecule to both visualize the cancer on a scanner and then treat it. Radionuclide therapy / Radioligand therapy (RLT): An integrated radiation treatment. A radioactive substance is attached to the homing molecule (the ligand) and injected into the bloodstream. It seeks out the cancer cells itself and destroys them with short-range radiation from within. PET scan (Positron Emission Tomography): An advanced imaging scan that shows the body's biological activity instead of just the physical organs. Curasight's specific productsuTRACE® (Diagnostics): Curasight's scanning method. Here, the homing molecule is coupled with a mild, radioactive tracer. This causes aggressive cancer tumors to "light up" on a PET scanner, so the doctor can see exactly how severe the cancer is. uTREAT® (Treatment): Curasight's treatment method. Here, the same homing molecule is reused, but now it is equipped with a much more powerful, radioactive substance. It functions as a homing missile that delivers radiation directly into the cancer cell without harming the surrounding healthy tissue.”
- ·12.5.I got a good tip - I thought - and bought, but with a drop of 17 k. it hasn't gone so well so far, and I think it's lying in a straight line and not really moving. Does anyone have an idea where the stock is going, or should I give up and sell?·14.5.The first ones I bought cost 20,40 DKK, and then I bought more as it fell all the way down to 1,98, which ended up giving me a GAK of 5,39. Now I am happy, but eagerly waiting to see it rise when we get more results·14.5.I did the same with gak at 7 now in 2 accounts. It was a good offer there at 2 kr😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | CAR | NON | ||
| 2 654 | NRD | NON | ||
| 94 | CAR | NON | ||
| 569 | NON | NON | ||
| 154 | NON | NON |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt